Note: This site has been translated into English from the Japanese original.
Medical products 4, Medical devices requiring control
Wound dressing and protecting hydrogel material for topical management
episil® has a mechanical action indicated for the managementof pain and relief of pain, by adhering to the mucosal surface of the mouth, soothing oral lesions including oral mucositis/stomatitis (may be caused by chemotherapy and/or radio therapy).
|Approved date||July 6, 2017|
|Launched date||May 16, 2018|
|Foreign Manufacturers||Camurus AB (Kingdom of Sweden)|
|Marketing Authorization Holder||Solasia Pharma K.K. (Japan)|
|Commercialization and promotion partner||Meiji Seika Pharma Co., Ltd. (Japan)|
*"episil®" launched in Japan by its commercialization and promotion partner, Meiji Seika Pharma Co., Ltd..
For more information, please link to Meiji website below; <only available in Japanese>
For overseas website, please link to Camurus AB website below;